Search

everythinglearnresearchcommunity

for

Search:↓

Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.

The conversation is about Jordan Peterson allegedly getting a hair transplant, with various users mocking his way of speaking and debating the ethics of him potentially hiding the procedure. Some users discuss the natural look of the transplant and the implications of getting one at an older age.

The conversation discusses the tension theory of baldness, suggesting that over-developed masseter muscles may harm hair follicles. Botox injections to relax these muscles reportedly led to an 18% increase in hair count in men with AGA.

A user is considering making a 2% clascoterone lotion from powder due to unavailability in their location. They plan to mix clascoterone powder with retinol lotion and use literature to determine the correct dosage.

A human trial involving verteporfin for hair regeneration, with the results showing some regrowth of 1-2 hairs in an area where a follicular unit was extracted. The conversation also suggested that future studies should involve higher doses and more frequent injections.

The discussion is about using ASCEplus HRLB exosomes for hair loss treatment, which combines 10 billion exosomes with growth factors, nutrients, biotin, and copper tripeptide. The treatment is expensive and typically administered via scalp injections, but in Europe, it's done with microneedling.

Potential treatments for hair loss, specifically the combination of liquid minoxidil and pyrilutamide, with some suggesting that adding finasteride may be beneficial.

A user is joining a clinical trial for Clascoterone, a drug approved for acne but being tested for hair loss. They previously tried finasteride with limited success and plan to share updates on their experience with the new treatment.

The user's experience with oral minoxidil, which resulted in under-eye wrinkles; other users sharing their experiences and advice regarding hair loss treatments such as topical minoxidil, finasteride, RU58841, and collagen supplementation.

Pelage plans to conduct two Phase 3 trials for PP405, a new hair loss treatment, which may take about a year to complete. Users discuss various hair loss treatments, including pyrilutamide, minoxidil, finasteride, and clascoterone, with some expressing impatience over the lengthy trial process compared to faster drug approvals like the COVID vaccine.

A user experienced significant swelling after a hair and beard transplant, possibly due to an allergic reaction or improper post-surgery care. Despite dissatisfaction with the clinic's handling of grafts and customer service, the user appreciates the clinic's skill in achieving natural hairline density.

Pelage executives' hairlines were discussed, with speculation about them using PP405 for hair regrowth. Concerns were raised about using untested drugs, with some suggesting executives might not risk using them without safety data.

The user experienced significant hair regrowth over five months using Locklabs oral tablets, with no side effects and only a minor shed. They dye their hair black to cover natural blonde, which may affect perceived hair density.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

PP405 shows promise in stimulating new terminal hair growth by activating dormant follicles, with no systemic adverse effects observed in a short-term trial. However, long-term efficacy remains unproven, and further trials are needed to confirm its potential as a hair loss treatment.

The user is dissatisfied with their hair transplant results from Asli Tarcan, citing poor donor area management and insufficient graft density. They advise against opting for cheaper procedures and express hope for future hair cloning solutions.

The post discusses a successful hair loss treatment involving a hair transplant, finasteride, and minoxidil. The user underwent a 2000 graft hair transplant at the hairline in a clinic in Sweden.

A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

User asked dermatologist for finasteride, received latanoprost and diprogenta cream instead. Others suggest latanoprost is expensive and not better than minoxidil, recommend trying another doctor for finasteride.

Topical tretinoin applied to the face may exacerbate hair loss in some individuals, potentially triggering conditions like frontal fibrosing alopecia. Experiences vary, with some users reporting no impact on hair, while others experience significant hair loss.

Kintor is launching pyrilutamide as a cosmetic for hair loss. Users discuss its potential, comparing it to Cosmerna.

The potential of using Verteporfin to prevent hair loss scars and possible regrowth, with two doctors currently testing it, although the price of a 15mg bottle is expensive.

The conversation discusses hair loss concerns, specifically traction alopecia and hair loss from acne. It mentions that sleeping on one side is unlikely to cause traction alopecia.

The user is experiencing intense hair shedding all over the scalp after applying pyrilutamide to the hairline and taking oral castor oil. They are also using topical finasteride and latanoprost, but are unsure which treatment is causing the shedding.

A 40-year-old male using microneedling, low-level laser therapy (LLT), and rosemary oil for hair regrowth. No finasteride or minoxidil is used.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

A 25-year-old is experiencing chronic telogen effluvium (TE) and androgenetic alopecia (AGA) after surgery, using finasteride, red light therapy, and supplements, and considering oral minoxidil despite heart concerns. They are unsure whether to start minoxidil before or after an upcoming surgery, which may trigger another hair shed.

The conversation is about a person considering participating in a study for Clascoterone, a topical cream for hair loss, and seeking advice on potential side effects. They have mild hair loss and are not currently using other treatments like finasteride.

Excess Vitamin A and topical retinoids can cause diffuse hair shedding. The user suspects their chronic telogen effluvium may be linked to using adapalene, a topical retinoid.